Market Signal Briefing

Key Takeaways LUNR shares surged 60.8% in three months, far outperforming the industry's 4.9% growth over the same period.LUNR's current ratio of 6.28 highlights strong liquidity and short-term financial flexibility.LUNR expanded lunar capabilities through the $800M Lanteris acquisition and key communications partnerships. Intuitive Machines Inc.’s (LUNR - Free Report) robust presence in the aerospace market, solid liquidity and strong solvency position are tailwinds. Given its growth prospects, LUNR makes for a solid investment option in the Zacks Aerospace sector.

Let’s focus on the factors that make this Zacks Rank #2 (Buy) company a strong investment pick at the moment.

Growth ProjectionsThe Zacks Consensus Estimate for 2026 loss per share is pegged at 11 cents, which reflects an improvement of 8.33% in the past 60 days.

The consensus estimate for 2026 sales stands at $456 million, which suggests a year-over-year jump of 108.7%.

LUNR’s long-term (three-to-five years) earnings growth rate is 26.67%.

LUNR Stock’s Solvency PositionLUNR’s times interest earned (TIE) ratio at the end of the third quarter of 2025 was 3.68. A TIE ratio of more than one indicates that the company will be able to meet its interest payment obligations in the near term without any problems.

LUNR’s LiquidityLUNR’s current ratio at the end of the third quarter of 2025 was 6.28. A current ratio of greater than one indicates the company’s ability to meet its future short-term liabilities without difficulties.

Intuitive Machines’ Lunar Infrastructure ExpansionLUNR is strengthening its position in the lunar economy through targeted acquisitions and partnerships. The company recently completed its $800 million acquisition of Lanteris Space Systems, formerly Maxar Space Systems, adding a well-established spacecraft manufacturing business with a strong track record across national security, civil and commercial programs. The transaction enhances Intuitive Machines’ vertical integration and expands its space infrastructure capabilities.

In December 2025, Intuitive Machines signed a strategic cooperation agreement with Leonardo and Telespazio to support interoperable communications and navigation services for lunar exploration. The collaboration links Telespazio’s lunar systems under the European Space Agency’s Moonlight program with Intuitive Machines’ Space Data Network used by NASA. Collectively, these initiatives position the company for sustained growth as lunar missions expand.

LUNR Stock Price PerformanceShares of LUNR have gained 60.8% in the past three months compared with the industry’s 3.2% growth.

Image Source: Zacks Investment Research

Other Stocks to ConsiderOther top-ranked stocks from the same industry are Draganfly (DPRO - Free Report) , Huntington Ingalls Industries (HII - Free Report) and Redwire Corporation (RDW - Free Report) , each carrying a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for DPRO’s 2026 sales is pinned at $13.6 million, which indicates year-over-year growth of 135.9%. The Zacks Consensus Estimate for loss is pinned at 47 cents per share, which indicates year-over-year improvement.

Huntington delivered an average earnings surprise of 14.52% in the last four quarters. The consensus estimate for HII’s 2026 sales is pegged at $12.66 billion, which calls for year-over-year growth of 4.9%.

Redwire’s long-term (three-to-five years) earnings growth rate is 26.1%. The Zacks Consensus Estimate for RDW’s 2026 sales stands at $476.9 million, which implies year-over-year growth of 46.2%.

Key Takeaways BXP is expected to post year-over-year revenue and FFO per share growth in fourth-quarter 2025 results.BXP's Q4 results likely mirror strong leasing activity and sustained demand for premium office assets.Analysts see Q4 revenues of $814.7 million and FFO per share of $1.80, modestly above the prior-year quarter. BXP, Inc. (BXP - Free Report) is slated to report fourth-quarter 2025 results on Jan. 27, after market close. The company’s quarterly results are likely to display a year-over-year rise in revenues and funds from operations (FFO) per share.

In the last reported quarter, this office real-estate investment trust (REIT) reported FFO per share of $1.74, which surpassed the Zacks Consensus Estimate of $1.72. The quarterly results reflected better-than-anticipated revenues on healthy leasing activity.

Over the preceding four quarters, BXP’s FFO per share surpassed the Zacks Consensus Estimate twice, missed in the other and met in the remaining period, the average beat being 0.74%. This is depicted in the graph below:

U.S. Office Market in Q4Per a Cushman & Wakefield report, U.S. office demand turned positive in the second half of 2025, marking a key inflection point for the sector. Leasing activity strengthened, vacancy is expected to peak later this year and demand is becoming more geographically widespread. Competition for premium office space has intensified, while sublease availability continues to narrow. With new construction starts largely absent, conversions and repurposing of office assets are playing a bigger role in shaping supply.

The demand improvement was evident in absorption trends. Net absorption for the broader U.S. office market turned positive in Q4 2025, ending 12 consecutive quarters of declines. While full-year 2025 absorption remained negative at 6.7 million square feet (msf), this marked a sharp improvement from the five-year annual average decline of 50.5 msf. Excluding five markets, the other 86 posted 11.1 msf of net absorption, with 50 U.S. markets turning positive in 2025—the strongest since 2019—highlighting a broad-based recovery.

Demand for Class A office assets is ubiquitous across U.S. markets. Class A absorption totaled 3.5 msf in Q4 2025 and reached 9.2 msf for the full year, reflecting growing competition for high-quality office space.

On the supply side, elevated construction costs and policy uncertainty have curtailed new development. Vacancy declined in nearly half of U.S. markets over the past year, with the national vacancy rate standing at 20.5% in Q4 2025, up just 30 basis points year over year. Sublease availability also trended lower across roughly 60% of markets. Meanwhile, office conversions and repurposing have exacerbated supply constraints, further tightening available space, even as developers begin evaluating new projects to address emerging shortages.      

BXP: Factors at PlayIn the context of the above U.S. office industry background, BXP is poised to gain from the growing preference for quality office spaces among tenants and its ability to offer such spaces. BXP’s properties are likely to have witnessed healthy leasing activity in the fourth quarter. Also, the return-to-office policies implemented by many companies are likely to drive the demand for BXP's strategically located, high-quality office properties.

Moreover, the company is actively boosting its portfolio through repositioning initiatives like acquisitions, the development of properties in core markets and shedding properties in non-core markets. This is likely to have lent a positive impetus to its leasing activity, boosting its top line in the reported quarter.

The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $814.7 million, implying a 2.1% increase from the prior-year quarter’s reported number. The estimate for full-year 2025 is pinned at $3.24 billion, indicating 2% growth year over year.

BXP’s activities in the to-be-reported quarter were inadequate in garnering analysts’ confidence. The Zacks Consensus Estimate for fourth-quarter FFO per share has remained unchanged at $1.80 over the past three months. However, it suggests a marginal increase from the year-ago quarter’s tally. Meanwhile, the consensus estimate for full-year 2025 FFO per share has moved upward by a cent to $6.90 over the past week.

What Our Quantitative Model Predicts for BXPOur proven model doesn’t conclusively predict a surprise in terms of FFO per share for BXP this quarter. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an FFO beat, which is not the case here.

BXP has an Earnings ESP of -0.07% and currently carries a Zacks Rank of 3. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.

Stocks That Warrant a LookHere are two stocks from the broader REIT sector — W.P. Carey (WPC - Free Report) and Host Hotels & Resorts (HST - Free Report) — you may want to consider, as our model shows that these have the right combination of elements to report a surprise this quarter.

W.P. Carey, scheduled to report quarterly numbers on Feb. 10, has an Earnings ESP of +1.06% and carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Host Hotels & Resorts, slated to release quarterly numbers on Feb. 18, has an Earnings ESP of +1.92% and carries a Zacks Rank of 3 at present.

Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.

BlackRock Core Bond Trust remains a hold due to inconsistent earnings, NAV decline, and questionable dividend coverage. BHK trades at a 3.53% discount to NAV, but this reflects ongoing portfolio and distribution challenges rather than a clear value opportunity. The fund's heavy reliance on net realized gains and aggressive leverage amplifies risk, especially in a persistently high-rate environment.

Scan QR code to install app

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

STX heads into Jan. 27 earnings with revenue expected to rise 16% YoY, strong AI-driven data center demand and solid margins.

Key Takeaways WTI has generated positive cash flow for 28 quarters with low-decline assets and a 90% drilling success rate.RES trades under $7 with no debt and 2026 earnings estimates rising 40% over the past 60 days.OIS operates in 25 countries with projected 2026 revenue growth of 44.1% and diverse offshore offerings. Oil prices have hovered near the $60-per-barrel level in recent months as oversupply concerns, rising inventories and easing geopolitical tensions have capped upside momentum. WTI crude has slipped below $60 at times, keeping pressure on producer economics and investor sentiment across the energy space. Against this backdrop, some investors are watching low-priced energy stocks for selective opportunities. Names such as W&T Offshore (WTI - Free Report) , RPC Inc. (RES - Free Report) and Oil States International (OIS - Free Report) stand out as sub-$10 stocks tied to different parts of the energy value chain that could benefit if conditions stabilize or improve.

Pressure on Producer Margins at Current PricesOil’s recent price action reflects a market caught between supply growth and modest demand expansion. The International Energy Agency (IEA) projects global oil demand growth of 930,000 barrels per day in 2026, but supply is expected to rise faster, creating a sizable surplus. Inventories have continued to build, weighing on prices even as short-term disruptions in Kazakhstan and Venezuela briefly offered support.

Benchmark crude prices remain well below levels seen a year ago, leaving many U.S. independent producers operating close to breakeven. Sustained sub-$60 pricing compresses margins, limits drilling activity and heightens financial strain, particularly for smaller operators with higher costs or shorter reserve lives. As a result, equity performance across the sector has remained uneven and volatile.

Distinguishing Temporary Weakness From Structural RiskRecent price weakness has been driven largely by oversupply and higher inventories, but not all of that pressure is for the long term. The IEA has suggested that fears of a huge oil glut may be exaggerated, and demand forecasts have been raised as global growth steadies after last year’s tariff disruptions. The result is a mixed backdrop, where short-term cycles play out alongside longer-term uncertainty.

For investors, the challenge is separating companies facing temporary pricing headwinds from those with deeper business risks. Balance sheet strength, asset quality and operational flexibility become more important when commodity prices linger near breakeven levels.

Diversification Appeal and Volatility Trade-OffsCheap energy stocks under $10 can improve accessibility and allow investors to diversify exposure across producers, service providers and equipment suppliers without committing large amounts of capital to a single position. However, lower share prices often come with amplified volatility. During downturns, these stocks can decline sharply, particularly when oil prices weaken or capital spending slows.

A disciplined approach focuses less on share price and more on financial resilience, industry positioning and sensitivity to oil price movements. Evaluating how companies manage costs, generate cash flow and navigate cycles can help investors approach sub-$10 energy stocks more prudently.

Against this backdrop, the following three stocks offer distinct business models and risk profiles tied to the current oil market landscape.

3 Stocks to Focus onW&T Offshore: The company is an independent oil and natural gas producer with a long-standing presence in the Gulf of America. Public since 2005, W&T Offshore holds working interests in 50 offshore fields across federal and state waters and controls more than 600,000 gross acres. Its asset base features low-decline reservoirs, strong well productivity and substantial remaining reserves, which have helped the company generate positive cash flow for over 28 consecutive quarters.

Founded in 1983, W&T Offshore has grown through targeted acquisitions and disciplined development. This Zacks Rank #2 (Buy) company has completed roughly $2.7 billion in Gulf of America acquisitions since its IPO and maintains a drilling success rate near 90%, supported by deep technical expertise. With reserves of 248 million barrels of oil-equivalent and daily production of 35.6 thousand barrels of oil-equivalent in the third quarter of 2025, WTI continues to focus on cost reductions, reserve life extension and a steady pipeline of organic and acquired growth opportunities. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

W&T Offshore beat the Zacks Consensus Estimate for earnings in three of the last four quarters and met in the other, with the average being 27.1%. WTI, with a share price of just $1.92, has a market capitalization of $281 million.

RPC, Inc.: It is a U.S.-based oilfield services provider offering a wide portfolio of equipment and solutions to exploration and production companies. Its operations span pressure pumping, coiled tubing, downhole tools, wireline, and rental equipment, serving key domestic regions such as the Permian Basin, Appalachia and the Gulf Coast, with a selective international presence. The Zacks Rank #3 (Hold) company operates through subsidiaries like Cudd Energy Services, Thru Tubing Solutions, Pintail Completions, and Patterson Services.

Known for its disciplined financial approach, RPC carries a debt-free balance sheet and has consistently returned excess free cash to its shareholders. The firm has steadily expanded its service mix, most recently through the acquisition of Pintail, adding wireline capabilities. With a track record of resilience in a cyclical industry, RPC leverages diversification and capital discipline to support customers while driving long-term value creation.

RES shares trade for less than $7 as of this writing. An incredible bargain for investors, the Zacks Consensus Estimate for 2026 revenues of RES indicates 6.4% growth. Over the past 60 days, the Zacks Consensus Estimate for the company’s 2026 earnings has moved up from 20 cents per share to 28 cents.

Oil States International: Oil States International supplies products and services across the oil and gas value chain, from drilling and completion to subsea, production, and infrastructure. It builds offshore equipment such as risers, cranes, winches, and subsea pipeline components, and supports vessels and rigs. The #3 Ranked company also delivers drilling and fishing services, perforating systems, and well completion tools.

Founded in 1937, Oil States has grown through more than 40 acquisitions into a global operator in over 25 countries. Headquartered in Houston, it serves energy, industrial, and military customers. Operations are organized into Offshore/Manufactured Products, Well Site Services, and Downhole Technologies, combining engineered equipment with consumable products and field support.

The Zacks Consensus Estimate for 2026 revenues of OIS indicates 44.1% growth. Currently trading under $9, Oil States has a four-quarter earnings surprise of 12.5% on average.

Nvidia Corp (NASDAQ:NVDA, XETRA:NVD) shares moved higher in early trade on Friday after a Bloomberg report said China is preparing to allow major technology firms to place orders for the company’s H200 artificial intelligence chips.

According to the report, Chinese officials have told the country’s largest tech companies, including Alibaba Group, that they can begin preparing orders for Nvidia’s H200 chips, signaling Beijing may be close to formally approving imports of advanced AI components.

Regulators have granted in-principle approval for Alibaba, Tencent Holdings and ByteDance to move to the next stage of purchase preparations, people familiar with the matter said. This stage allows the companies to discuss details such as required volumes, according to the sources. 

Bloomberg also reported that Beijing is expected to encourage companies to purchase a certain amount of domestically produced chips as a condition of approval, though no specific thresholds have been set.

Wedbush analysts said the development could be meaningful for US chipmakers. “Per Bloomberg, China has told large CSPs that they can prepare orders for H200 parts and discuss specifics of such orders with NVDA, suggesting the country is close to formally approving imports of the US AI chips,” the analysts wrote.

They believe such an outcome “would represent a significant near-term positive for NVDA (and AMD) given the size of the China market, the magnitude of past orders, and previously reported speculated order figures for H200s from large China CSPs assuming H200 shipments are allowed.”

Shares of Nvidia were 1.6% higher on the news, while Advanced Micro Devices Inc (NASDAQ:AMD, XETRA:AMD) added 2.8%.

January 23, 2026 08:30 ET  | Source: Alico, Inc.

FORT MYERS, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) today announced that the Company will release financial results for the first quarter ended December 31, 2025, on Wednesday, February 4, 2026 after market close.

The Company will host a conference call to discuss its financial results on Thursday, February 5, 2026, at 8:30 am Eastern Time. Interested parties may join the conference call by dialing 1-800-245-3047 in the United States and 1-203-518-9765 from outside of the United States. The participant identification to join the conference call is ALICO.

A telephone replay will be available on Thursday, February 5, 2026 approximately three hours after the call concludes, and will be available through Thursday, February 19, 2026. Listeners in the United States may dial 1-844-512-2921 and international listeners may dial 1-412-317-6671. The passcode for the playback is 11160814.

About Alico

Alico, Inc. (Nasdaq: ALCO) is a Florida-based agribusiness and land management company with over 125 years of experience. Following its strategic transformation in 2025, Alico operates as a diversified land company with approximately 49,537 acres across 8 Florida counties as of September 30, 2025. The Company focuses on strategic land development opportunities and diversified agricultural operations, leveraging its extensive land portfolio to create long-term shareholder value while maintaining its commitment to responsible land stewardship and conservation. Learn more about Alico at www.alicoinc.com.

Investor Contact:
John Mills
ICR
(646) 277-1254
[email protected]

Brad Heine
Chief Financial Officer
(239) 226-2000
[email protected]

NEW YORK CITY, NY / ACCESS Newswire / January 23, 2026 / The OLB Group, Inc. (NASDAQ:OLB) ("OLB" or the "Company"), a diversified fintech company providing payment processing and digital asset technology solutions, today announced that it has entered into a securities purchase agreement for the purchase and sale of 2,166,666 shares of its common stock at purchase price of $0.60 per share for an aggregate price of approximately $1.3 million before deducting commissions and expenses of the offering. In addition, in a concurrent private placement, the Company will issue warrants to purchase up to 2,166,666 shares of common stock. The warrants have an exercise price of $0.78 per share, are exercisable commencing six months after issuance and will have a term of five years from the issuance date. The closing of the offering is expected to occur on or about January 26, 2026, subject to the satisfaction of customary closing conditions.

D. Boral Capital LLC is acting as exclusive placement agent for the offering.

The proposed offering of the common stock described above is being offered by the Company pursuant to a "shelf" Registration Statement on Form S-3 (File No. 333-280347) filed with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC on July 2, 2024, and the accompanying prospectus contained therein. The offering is being made only by means of a prospectus supplement and accompanying prospectus. A final prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC, which may be obtained, when available, from D. Boral Capital LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022 by email to [email protected], or by calling (212) 970-5150.

The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and, along with the shares of common stock underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About The OLB Group, Inc.
The OLB Group, Inc. (NASDAQ:OLB) is a diversified fintech company providing innovative payment processing solutions, digital asset technology, and omnichannel commerce platforms. Through its SecurePay payment gateway and complementary services, OLB enables businesses to accept and process payments seamlessly across multiple channels while leveraging emerging technologies in digital assets and AI-driven commerce solutions.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, including statements regarding the anticipated closing of the offering. These forward-looking statements are often indicated by terms such as "aim," "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "likely," "look forward to," "may," "objective," "plan," "potential," "predict," "project," "should," "slate," "target," "will," "would" and similar expressions and variations thereof. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. OLB's actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 15, 2025, as amended on April 29, 2025, and in our subsequent filings with the SEC. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

The OLB Group, Inc.
Investor Relations
Email: [email protected]
Phone: (212) 278-0900 EXT 333

SOURCE: The OLB Group, Inc.

MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF, FRA:0C0) announced the closing of its previously announced non-brokered private placement, raising gross proceeds of $2 million.

The Saskatoon-based company said it issued 4 million units at a price of $0.50 per unit under the offering, which was completed pursuant to the listed issuer financing exemption. Each unit consists of one common share and one common share purchase warrant.

Each whole warrant is exercisable for a period of 60 months from the date of closing and entitles the holder to purchase one additional common share at an exercise price of $0.70 per share.

MustGrow said it intends to use the net proceeds from the financing for inventory production of its mustard-derived organic biofertility product TerraSante, inventory for agricultural products to be sold through its Canadian distribution platform NexusBioAg, and for working capital and general corporate purposes.

HomeEarnings AnalysisUtilities 

SummaryNextEra Energy, Inc. sits at the center of the U.S. power demand boom, driven by AI infrastructure and population growth, combining a highly predictable regulated utility with a faster-growing renewable arm.The business is executing almost flawlessly, with visible capex, stable regulated returns, and a long-term EPS growth target above 8%.The problem is not the fundamentals but the valuation: the market has already priced in sustained execution, leaving little margin of safety at current multiples. oliver de la haye/iStock via Getty Images

Introduction Take a look at the bar graph below.

It is very likely that you have either seen it already or have stumbled across similar data. Power demand is booming, mainly because of the AI infrastructure buildout (43% of the expected demand

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© bigjom jom / Shutterstock.com

Investors holding Invesco Emerging Markets Sovereign Debt ETF (NYSEARCA:PCY) have seen shares rise 14% over the past year, but the fund has flatlined since early December. Trading near $21.60, PCY sits at a crossroads where two forces will determine its direction: the Federal Reserve’s next move and emerging market economic health.

What the Fed Does Next Matters More Than You Think The biggest driver for PCY over the next 12 months is U.S. interest rate trajectory. When the Fed cuts rates, two things benefit emerging market sovereign debt. First, U.S. Treasury yields fall, making PCY’s 6.1% yield more attractive to income-focused investors. Second, rate cuts typically weaken the dollar, reducing the debt servicing burden for emerging market governments that borrow in dollars.

Prediction markets show investors increasingly expect the Fed to resume cutting rates in 2026 after pausing earlier this year. The central bank cut rates in 2024, but the pace and magnitude of future cuts remain uncertain. If inflation proves stickier than expected or the economy stays resilient, the Fed could hold rates higher for longer. That scenario would strengthen the dollar and pressure PCY’s holdings, particularly bonds from countries with weaker fiscal positions.

Watch the monthly Consumer Price Index releases and quarterly Fed policy meetings. When core inflation trends below 3% and the Fed signals dovish intentions, PCY tends to benefit. Conversely, hawkish Fed commentary or inflation surprises above 3.5% historically weigh on the fund.

The Credit Quality of What PCY Actually Owns Beyond macro forces, PCY’s performance depends on the specific countries in its portfolio. The fund holds dollar-denominated sovereign debt from emerging markets, meaning returns hinge on whether these governments can service their obligations without default or restructuring.

Recent technical analysis suggests the fund is trading in a neutral mid-channel pattern with long-term positive bias, but that bias only holds if underlying credit quality remains stable. Institutional investors have shown mixed signals, with some reducing positions while others add exposure. This divergence suggests uncertainty about emerging market fundamentals.

Investors should review Invesco’s monthly fact sheets and holdings files to monitor country exposure changes. Pay attention to concentration increases in higher-risk sovereigns or shifts toward investment-grade credits. The prospectus details the index methodology, which uses tier weighting based on market capitalization and liquidity.

The combination of Fed policy direction and emerging market credit stability will determine PCY’s path forward. If the Fed cuts rates while emerging market fundamentals hold steady, the fund could extend recent gains. If either factor deteriorates, expect volatility.

If You have $500,000 Saved, Retirement Could Be Closer Than You Think (sponsor) Retirement can be daunting, but it doesn’t need to be.

Imagine having an expert in your corner to help you with your financial goals. Someone to help you determine if you’re ahead, behind, or right on track. With SmartAsset, that’s not just a dream—it’s reality. This free tool connects you with pre-screened financial advisors who work in your best interests. It’s quick, it’s easy, so take the leap today and start planning smarter!

Don’t waste another minute; get started right here and help your retirement dreams become a retirement reality. (sponsor)

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)State Street Global Advisors & AffiliatesCompany dealt inAvadel Pharmaceuticals plcClass of relevant security to which
the dealings being disclosed relate (Note 2)$0.01 ordinary shares

Date of dealing22nd January 2026 2. INTERESTS AND SHORT POSITIONS
(110)   Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 LongShort Number(%)Number(%)(1) Relevant securities2,329,0212.39111%  (2) Derivatives (other than options)N/AN/A  (3) Options and agreements to
purchase/sellN/AN/A  Total2,329,0212.39111%          (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)        

Class of relevant security:LongShort Number(%)Number(%)(1) Relevant securitiesN/A   (2) Derivatives (other than options)N/A   (3) Options and agreements to purchase/sellN/A   TotalN/A    3. DEALINGS (Note 4)
(110)   Purchases and sales

Purchase/saleNumber of relevant securitiesPrice per unit (Note 5)Purchase1,12521.53Purchase1821.53         
(b) Derivatives transactions (other than options transactions)

Product name,
e.g. CFDNature of transaction(Note 6)

Number of relevant securities(Note 7)

Price per unit(Note 5)

N/A            
(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name,
e.g. call optionWriting, selling,
purchasing
varying etc.Number of
securities to which
the option relates
(Note 7)Exercise
priceType, e.g.
American,
European etc.Expiry
dateOption money
paid/received
per unit (Note 5)N/A       (ii) Exercising

Product name,
e.g. call optionNumber of securitiesExercise price per
unit (Note 5)N/A   (d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction
(Note 8)DetailsPrice per unit
(if applicable) (Note 5)N/A   4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.N/A Is a Supplemental Form 8 attached? (Note 9)
NO
Date of disclosure

23rd-January-2026
Contact name
Divya K

        
Telephone number                                

+918067452364
If a connected EFM, name of offeree/offeror with which connected
N/A
If a connected EFM, state nature of connection (Note 10)
N/A

January 23, 2026 08:42 ET  | Source: Rathbones Group PLC

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offereeThe Unite Group Plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure22/01/2026(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
        If it is a cash offer or possible cash offer, state “N/A”Yes 2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:25p Ord InterestsShort positions Number%Number%(1)   Relevant securities owned and/or controlled:583,7750.11%  (2)   Cash-settled derivatives:    (3)   Stock-settled derivatives (including options) and agreements to purchase/sell:            TOTAL:

583,7750.11%   All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages:  3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit25p Ordinary SharesSale620567.45p (b)        Cash-settled derivative transactions

Class of relevant securityProduct description
e.g. CFDNature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit      (c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType
e.g. American, European etc.Expiry dateOption money paid/ received per unit         (ii)        Exercise

Class of relevant securityProduct description
e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit      (d)        Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing
e.g. subscription, conversionDetailsPrice per unit (if applicable)     4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”None (b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”None (c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?No Date of disclosure:23/01/2026Contact name:Callum Ridley – Compliance Department Telephone number:0151 243 7037 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

“Druggable Target to Treat Retinal Degeneration”

Palm Beach Gardens, FL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the “Company”), a company developing metformin-based eye drops for the treatment of degenerative eye diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for Canadian Patent Application No. 3,151,011, entitled “Druggable Target to Treat Retinal Degeneration.”

Curative is the exclusive worldwide licensee of this technology pursuant to a patent license agreement with the National Eye Institute (NEI), part of the National Institutes of Health (NIH). The invention, developed under the leadership of Dr. Kapil Bharti and his team at the NEI, identifies a novel pharmacological target with potential relevance to the progression of retinal degenerative diseases.

“This allowance in Canada represents an important step in our strategy to build a global intellectual property portfolio supporting our ophthalmology platform,” said Paul Michaels, Chairman and President of Curative Biotechnology.

The Canadian patent includes 22 allowed claims, including claims directed toward topical ocular delivery approaches relevant to metformin-based formulations, which align with the Company’s intended route of administration. The patent is expected to formally issue in the coming months.

The Company has previously announced plans to expand development of its metformin-based eye drop program into select canine (K9) retinal degenerative indications, where disease mechanisms closely parallel those observed in human retinal degeneration. This represents a parallel development pathway that may enhance the overall value of the platform while addressing unmet needs in veterinary ophthalmology.

Initial target indications include:

Progressive Retinal Atrophy (PRA)Progressive Rod and Cone Disease (PRCD), a rare retinal disease in canines Future Curative Biotechnology Press Releases and Updates

Interested shareholders and investors may request notification of future press releases and corporate updates by emailing [email protected].

About Curative Biotechnology, Inc.

Curative Biotechnology, Inc. is a development-stage biomedical company focused on the identification and development of novel therapeutic approaches for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with an emphasis on rare disease indications. Curative currently maintains programs in degenerative eye disease, infectious disease, and neuro-oncology.

The Company’s primary focus is its degenerative eye disease platform, supported by a worldwide exclusive license from the National Eye Institute (NEI) at the National Institutes of Health (NIH). Its initial therapeutic candidate is a metformin-based reformulation intended for the treatment of intermediate and late-stage Age-Related Macular Degeneration (AMD). A first-in-human clinical trial is planned for 2026, subject to regulatory and operational readiness, under a Cooperative Research and Development Agreement (CRADA) with the NEI.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding patent issuance, development strategies, clinical timelines, and potential therapeutic applications. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially.

Such risks include, among others, uncertainties related to intellectual property protection, regulatory approvals, clinical development, access to capital, reliance on third-party collaborators, market acceptance, and the Company’s ability to execute its business strategy.

Readers are encouraged to review the Company’s disclosures filed with OTC Markets for a more complete discussion of risk factors. The Company undertakes no obligation to update forward-looking statements, except as required by law.

Contact:

Paul Michaels
Executive Chairman
Direct: 917-492-8855

Investor Relations
Curative Biotechnology, Inc. (CUBT)
[email protected]

Analyst’s Disclosure: I/we have a beneficial long position in the shares of DIVO, SCHD, VYM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: I am not an investment advisor or professional. This article is my own personal opinion and is not meant to be a recommendation of the purchase or sale of stock. The investments and strategies discussed within this article are solely my personal opinions and commentary on the subject. This article has been written for research and educational purposes only. Anything written in this article does not take into account the reader’s particular investment objectives, financial situation, needs, or personal circumstances and is not intended to be specific to you. Investors should conduct their own research before investing to see if the companies discussed in this article fit into their portfolio parameters. Just because something may be an enticing investment for myself or someone else, it may not be the correct investment for you.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Key Takeaways VLO may benefit from soft oil prices as its refining operations can buy crude at a cheaper rate.Valero stands to gain as EIA expects rising global inventories and projects lower average WTI prices in 2026.VLO shares rose 38.1% over the past year, while earnings estimates for 2026 saw upward revisions. With West Texas Intermediate (WTI) oil prices currently trading below $60 per barrel, according to data from Oilprice.com, which is significantly lower than a year ago, the overall energy industry is now highly uncertain. However, unlike many other energy players, Valero Energy Corporation (VLO - Free Report) is likely to gain from the ongoing crude pricing environment.

This is because Valero Energy is a leading refining company with the capacity to process 3.2 million barrels of oil daily. VLO is now able to purchase oil at a lower cost, enabling the production of end products, such as gasoline and distillates. Additionally, crude prices are likely to remain soft in the coming days, as the U.S. Energy Information Administration (“EIA”) expects global oil inventories to continue increasing. 

EIA projects the spot average West Texas Intermediate price for 2026 at $52.21 per barrel, lower than $65.40 per barrel for 2025. Thus, Valero Energy, which generates significant margin from its refining activities, is likely to benefit from soft oil prices.

PSX & PARR Also Poised to GainPhillips 66 (PSX - Free Report) and Par Pacific Holdings Inc. (PARR - Free Report) , two other well-known refiners, are also likely to benefit from the ongoing relatively low oil prices.

Refining operations continue to contribute to PSX’s earnings. Moreover, Phillips 66 expects refining to continue to back its bottom line considerably after its midstream activities. 

Par Pacific is mainly a refining company with the capacity to process 219,000 barrels of oil daily. Notably, given its exposure to Canadian heavy oil, which is cheaper than lighter crude, Par Pacific is likely enjoying a cost advantage.

VLO’s Price Performance, Valuation & EstimatesShares of VLO have gained 38.1% over the past year compared with the 20.1% rise of the composite stocks belonging to the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, VLO trades at a trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 9.01X. This is above the broader industry average of 4.64X.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for VLO’s 2026 earnings has seen upward revisions over the past seven days.

Image Source: Zacks Investment Research

VLO currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of AMAT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

SoFi Technologies Inc.’s (NASDAQ: SOFI) chief executive officer stated at a conference last year that the fintech company is targeting 30% member growth and 20% revenue growth. Its stock is trading marginally lower than a week ago. A proposed 10% credit interest cap could boost fintech companies, but SoFi faces some profit-taking pressure due to its premium valuation compared to peers. Also, the company has announced a strategic partnership with GoTu Technology, a marketplace for dental professionals. The share price is still up 24.4% from six months ago, outperforming the S&P 500 and Nasdaq. SoFi’s one-year gain is 48.3%.

Worries about recession had an impact on fintech stocks like SoFi last year. Some analysts see it as having a steep premium, while others anticipate decades of growth potential. The overall sentiment could be described as cautious optimism. SEC filings revealed that some asset management firms increased their stakes in SoFi in the second half of the year.

SoFi has been exploring re-entry into the crypto and blockchain space. It became the first nationally chartered bank to offer cryptocurrency trading, and it announced the launch of a new, actively managed exchange-traded fund (ETF) focused on artificial intelligence. SoFi also announced a partnership with Lightspark to leverage blockchain technology for international money transfers.

SoFi made its public debut on June 1, 2021, through a merger with a special purpose acquisition company (SPAC), Social Capital Hedosophia Holding Corp. V. Before the merger, the company’s original name was Social Finance. It started as a student loan financing firm before expanding into loans, mortgages, and other financial products. After the SPAC acquisition, SoFi was equipped with substantial capital to enhance its technology stack to better scale its 2020 acquisition of Galileo. The Galileo platform was developed to deploy a wide range of financial services quickly, giving SoFi the tools to bring numerous financial products to a mass market.

SoFi went public at $10 per share, and the price quickly jumped 150%, but the stock’s performance was lackluster afterward. However, investors only care about what happens from this point on, particularly over the next one, three, and five years. Let’s crunch the numbers and share our best estimate for SoFi’s future share price. No one has a crystal ball, and even the Wall Street “experts” are often wrong more than they are right in predicting future stock prices. But we provide our revenue and earnings projections as part of our peer-to-peer valuation.

SoFi’s Recent Performance The table below summarizes performance in share price, revenue, and profits (net income) since its IPO.

Year Share Price  Revenue* Net Income* 2021 $12.50 $977.3 ($483.9) 2022 $15.81 $1,519.2 ($320.4) 2023 $4.62 $2,067.8 ($300.7) 2024 $15.40 $2,343.5 ($113.3) *Revenue and net income in millions

In the past four years, SoFi has more than doubled its revenue, but that top-line growth also came with a jump in total operating costs, particularly the $720 million in sales and marketing expenses in 2023. However, the increases in operating costs are money well spent with in-house technology improvements and member-generating marketing spending.

SoFi has hit an inflection point in profitability and has done a stellar job of expanding revenue and improving earnings per share (EPS).

As SoFi’s revenue grows, it becomes more profitable, meaning its costs per customer decrease. This scalability is important because it indicates that as the company grows, it will become even more profitable. Given that the industry is growing and SoFi is outperforming its peers, there is strong optimism that SoFi’s earnings per share will continue to rise. Its fiscal first-quarter report is scheduled for January 30.

Key Drivers of SoFi’s Stock Performance

Expanding its services and retaining customers.

Expansion Financial Services: SoFi’s ambition to become a one-stop shop for financial services will likely drive future growth. The company plans to continue expanding its product lineup—including new lending products, investment options, and insurance services—to cater to a broader range of financial needs.

Bank Charter and Deposit Base Expansion: Obtaining a national banking charter allows SoFi to use its growing deposit base to fund lending operations more efficiently. This access to lower-cost funds is expected to drive net interest income growth, enhancing profitability as SoFi scales its banking operations.

Cross-Selling and Customer Retention: SoFi’s strategy of cross-selling its wide array of financial products aims to increase the average number of products per customer. With this integrated approach, it aims to improve customer retention and lifetime value, thereby boosting overall revenue and profitability.

SoFi’s Share Price Estimates 2026-2030

Wall Street remains cautious for now.

The Wall Street consensus one-year price target for SoFi Technologies is $27.11, which is 3.9% higher than the current share price. Note that of 22 analysts covering the stock, only six recommend buying shares.

24/7 Wall St. is more bullish on the stock, with a $35.70 target price by year’s end 2026. That target represents almost a 37% gain over the current share price.

Year Est. Revenue ($B)  Est. Net Income ($B)  Est. EPS Normalized Price to Sales Multiple Est. Market Cap ($B) 2025 $2.84 $0.32 $0.21 3.5 $9.94 2026 $3.45 $0.584 $0.43 3.5 $12.08 2027 $3.79 $0.707 $0.62 3.5 $13.27 2028 $4.33 $0.902 $0.83 3.5 $15.16 2029 $4.84 $1.096 $1.02 3.5 $16.94 2030 $5.34 $1.279 $1.10 3.5 $18.69 24/7 Wall St. compared other fintech/lenders when deciding on our price-to-sales valuation of 3.5 times for the entire time frame of our analysis. Included in the analysis were Block Inc. (NYSE: XYZ), PayPal Holdings Inc. (NASDAQ: PYPL), Upstart Holdings Inc. (NASDAQ: UPST), LendingClub Corp. (NYSE: LC), and Affirm Holdings Inc. (NASDAQ: AFRM), which gives us a blended valuation of around 3.3x sales.

By the end of the decade, we estimate SoFi’s stock price will be $55.30 per share with 10% year-over-year revenue growth. Our estimated price would more than double the current share price.

Year Price Target Change From Current Price 2026 $35.70 36.8% 2027 $39.26 50.5% 2028 $44.85 71.9% 2029 $50.12 92.1% 2030 $55.30 112.0% Can SoFi Do What JPMorgan Has Been Unable to in 226 Years?

The $1,500 Bonus That’s Almost Too Good To Be True Raisin is paying savers up to $1,500 in cash bonuses with code ‘HEADSTART’ just for opening and funding a new high-yield savings or CD account through its platform.

With quarterly payouts, no fees, and access to competitive rates from federally insured banks and credit unions, this limited-time offer rewards you all year long, and the more you save, the more you earn.

Click here to see exactly how much you could qualify for and how to claim a $1,500 bonus with code ‘HEADSTART’ before the deadline.

Key Takeaways VSAT will offer complimentary in-flight Wi-Fi to KLM Flying Blue members across narrowbody & regional fleets.KLM plans rapid deployment on 68 aircraft using Viasat's future-ready connectivity platform.VSAT expects low single-digit fiscal 2026 revenue growth, with double-digit gains in aviation services. Viasat, Inc. (VSAT - Free Report) has announced that it will begin offering fast, full and free in-flight connectivity (IFC) for KLM Royal Dutch Airlines, including KLM Cityhopper. The complimentary service will be rolled out across KLM’s narrowbody and regional aircraft and will be available to members of the airline’s Flying Blue loyalty program, with passengers able to sign up easily during their journey. This move positions KLM at the forefront of Europe’s in-flight Wi-Fi evolution, as the airline plans a rapid deployment across a total of 68 aircraft using Viasat’s next-generation connectivity solution.

Building on a partnership that has spanned more than six years, KLM is leveraging Viasat’s future-ready technology to raise the standard for passenger connectivity across European airspace.

Management highlighted that full, fast and free Wi-Fi represents the future of air travel, noting that the expanded collaboration with KLM will help deliver a superior, more personalized onboard experience. Also, management stated that Viasat’s ability to provide flexible, airline-specific solutions aligns with KLM’s long-term goals and enhances overall passenger satisfaction.

The announcement comes amid growing demand for seamless and reliable IFC across Europe, as passenger expectations continue to rise alongside rapid technological change. Viasat’s advanced connectivity platform enables KLM to meet current expectations while remaining compatible with future network upgrades, ensuring long-term performance and scalability.

As one of the world’s longest-operating airlines, serving more than 160 destinations this winter, 92 of them in Europe, KLM’s rollout of full, fast and free Wi-Fi marks a significant milestone for European aviation and further reinforces Viasat’s position as a leading provider of innovative IFC solutions worldwide.

Viasat is gaining from the growing adoption of in-flight Wi-Fi services in commercial aircraft, which is proving conducive to business growth. Viasat’s impressive bandwidth productivity sets it apart from conventional and lower-yield satellite providers that run on incumbent business models. Viasat has a competitive advantage in bandwidth economics, global coverage, flexibility and bandwidth allocation, which makes it believe that mobile broadband will act as a profit churner with a significant improvement in IFC revenues.

For fiscal 2026, management expects low single-digit revenue growth and flattish adjusted EBITDA year over year. Viasat anticipates the Communication Services segment’s revenue performance to be flat due to low double-digit growth in aviation services, partially offset by a lower rate of declines in fixed services and other. DAT revenue growth is anticipated to be in the mid-teens, primarily driven by strong double-digit growth in both information security and cyber defense, and space and mission systems.

VSAT Stock’s Price PerformanceViasat currently has a Zacks Rank #3 (Hold). Shares of Viasat have surged 284.7% over the past year compared with the Wireless Equipment industry’s growth of 27.1%.

Image Source: Zacks Investment Research

Stocks to Consider From the Computer and Technology SpaceSome better-ranked stocks from the broader technology space are Clearfield, Inc. (CLFD - Free Report) , Ubiquiti Inc. (UI - Free Report) and Motorola Solutions, Inc. (MSI - Free Report) . CLFD sports a Zacks Rank #1 (Strong Buy) while UI and MSI currently carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Clearfield’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 92.47%. In the last reported quarter, CLFD delivered an earnings surprise of 44.44%. Its shares have lost 20.1% in the past year.

UI’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 54.15%. In the last reported quarter, Ubiquiti delivered an earnings surprise of 39.52%. Its shares have surged 26.1% in the past six months.

Motorola Solutions’ earnings beat the consensus estimate in each of the trailing four quarters, with the average surprise being 5.5%. MSI’s long-term earnings growth rate is 9.1%. Its shares have declined 16.1% in the past year.

Vancouver, British Columbia--(Newsfile Corp. - January 23, 2026) - Kenorland Minerals Ltd. (TSXV: KLD) (OTCQX: KLDCF) (FSE: 3WQ0) ("Kenorland" or the "Company") announces that it has granted stock options (the "Options") to its directors, officers, employees and consultants to acquire a total of 4,080,000 common shares of the Company at an exercise price of $3.31 per share for a period of five years. The Options vest one-third immediately, followed by one-third every year thereafter.

About Kenorland Minerals

Kenorland Minerals Ltd. (TSXV: KLD) is a well-financed mineral exploration company focused on project generation and early-stage exploration in North America. Kenorland's exploration strategy is to advance greenfields projects through systematic, property-wide, phased exploration surveys financed primarily through exploration partnerships including option to joint venture agreements. Kenorland holds a 4% net smelter return royalty on the Frotet Project in Quebec, which is owned by Sumitomo Metal Mining Canada Ltd. The Frotet Project hosts the Regnault gold system, a greenfields discovery made by Kenorland and Sumitomo Metal Mining Canada Ltd. in 2020, which contains an Inferred Mineral Resource of 14.5 Mt at 5.47 g/t Au for 2.55 Moz of gold. Kenorland is based in Vancouver, British Columbia, Canada.

Further information can be found on the Company's website www.kenorlandminerals.com.

On behalf of the Board of Directors,

Zach Flood
President, CEO & Director

Cautionary Statement Regarding Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (together, "forward-looking statements") within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Generally, forward-looking statements can be identified by the use of terminology such as "plans", "expects", "estimates", "intends", "anticipates", "believes" or variations of such words, or statements that certain actions, events or results "may", "could", "would", "might", "will be taken", "occur" or "be achieved". Forward-looking statements involve risks, uncertainties and other factors disclosed under the heading "Risk Factors" and elsewhere in the Company's filings with Canadian securities regulators, that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing these forward-looking statements are reasonable based upon the information currently available to management as of the date hereof, actual results and developments may differ materially from those contemplated by these statements. Readers are therefore cautioned not to place undue reliance on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by applicable law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/281347

Source: Kenorland Minerals Ltd.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, CEO Dr Raza Bokhari joined Steve Darling from Proactive https://youtu.be/8EErx6aQEXs to announce that the company was honored with the opportunity to ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square, marking the one-year anniversary of Medicus' listing on the Nasdaq exchange.

Dr. Bokhari said the milestone reflects the company's progress since going public and highlights its continued focus on disciplined execution across a streamlined and strategically selected clinical portfolio. Since its Nasdaq debut, Medicus has concentrated on advancing key therapeutic assets through Phase 2 proof-of-concept studies while actively pursuing licensing opportunities and strategic partnerships with established pharmaceutical companies that are well positioned to manage late-stage development and global commercialization.

Medicus' current development pipeline is anchored by two lead programs. SkinJect is a localized, immunogenic precision therapy being developed for the treatment of basal cell carcinoma, the most common form of skin cancer. The company estimates SkinJect addresses a market opportunity of approximately $2 billion.

The pipeline also includes Teverelix, a next-generation gonadotropin-releasing hormone (GnRH) antagonist designed for patients with advanced prostate cancer who are at high cardiovascular risk and susceptible to acute urinary retention relapse. Medicus estimates the combined market opportunity for its pipeline assets at approximately $6 billion. The company announced today that the royalty rate payable on worldwide net sales of Teverelix has been reduced from ~4% to 2%, with the royalty term clarified on a country-by-country basis in line with standard industry practice. The company says this makes Teverelix more attractiveness for future partnering.

The video of the proactive interview is available by clicking on this link https://youtu.be/8EErx6aQEXs

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
[email protected]

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
[email protected]

About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq:MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries across three continents.

SkinJect Inc., a wholly owned subsidiary of Medicus Pharma Ltd., is a development-stage life sciences company focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumor cells. The Company completed a Phase 1 study (SKNJCT-001) in March of 2021, which met its primary objective of demonstrating safety and tolerability; the study also describes the efficacy of the investigational product doxorubicin-containing microneedle arrays (D-MNA), with six participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (MoU) with Helix Nanotechnologies, Inc. (HelixNano), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next-generation gonadotrophin-releasing hormone (GnRH) antagonist, as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in 50 patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met, with the probability dropping to 82.5% by Day 42.

In January 2023, the U.S. Food and Drug Administration (FDA) reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev's proposed Phase 3 trial design for Teverelix. This milestone supports the Company's clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, the FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, the FDA approved the Phase 2b study design in AURr covering 390 patients.

In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the FDA to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SkinJect under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect in this rare disease population.

In November 2025, the Company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study-wide governance approval, confirming compliance with UK Good Clinical Practice and National Health Service capacity and capability standards.

In December 2025, the Company announced that it has successfully completed enrolment of 90 patients in the United States for Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The Company expects to release topline results for SKNJCT-003 in the first quarter of 2026 and secure an end-of-Phase 2 meeting with the FDA in the first half of 2026.

In December 2025, Medicus announced a non-binding letter of intent with Reliant AI Inc., a decision-intelligence company specializing in generative AI for the life sciences industry, to collaborate on the development of an AI-driven clinical data analytics platform. Subject to execution of definitive agreements, the platform is expected to support capital-efficient clinical development through data-driven dynamic clinical-site selection, patient stratification and enrollment forecasting. The initial phase of the collaboration is expected to support an upcoming Teverelix clinical study planned for 2026, with potential expansion into later-stage development programs in collaboration with a strategic partner.

Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company's leadership and prospects, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect™), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SkinJect™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr, high CV risk prostate cancer, women's health indications like endometriosis, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano's proprietary mRNA vaccine platform with Medicus's proprietary microneedle array (MNA) delivery platform, the Company's aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, including with respect to the Company's submission for approval in the FDA Commissioner's National Priority Voucher program, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the Company's expectation to release topline results for SKNJCT-003 in the first quarter of 2026 and to secure an EOP2 meeting with the FDA in the first half of 2026, entry into definitive documents with Reliant and the expected terms thereof, engaging in proposed Medicus-sponsored studies currently contemplated in the Reliant non-binding letter of intent and the expected benefits thereof, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "could," "designed," "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", "potential" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported certain unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance for the full year ending December 31, 2026.

Selected Fourth Quarter and Full Year 2025 Preliminary Financial Results (Unaudited):

Net revenue for the fourth quarter of 2025 is expected to be in the range of $27.2 million to $27.7 million, an increase of approximately 3% to 5%, compared to $26.3 million in the fourth quarter of 2024. As previously disclosed, the Company experienced growth in sales of BIASURGE® Advanced Surgical Solution (“BIASURGE”) in the fourth quarter of 2024, as a result of supply chain issues and shortages of intravenous fluids and saline solutions experienced by the broader industry due to Hurricane Helene. Excluding approximately $1.8 million of BIASURGE sales in the fourth quarter of 2024, net revenue in the fourth quarter of 2025 is expected to increase approximately 11% to 13% year-over-year.(1) Net revenue for the full year 2025 is expected to be in the range of $102.7 million to $103.2 million, an increase of approximately 19%, compared to $86.7 million for the full year 2024. Excluding the aforementioned $1.8 million of BIASURGE sales in the fourth quarter 2024, net revenue for the full year 2025 is expected to increase approximately 21% to 22% year-over-year.(1) As of December 31, 2025, the Company had cash of approximately $16.6 million and long-term debt of $46.0 million, compared to cash of $15.9 million and long-term debt of $30.7 million as of December 31, 2024. Fourth Quarter and Recent Operational Highlights:

On December 10, 2025, the Company provided an update on progress related to its strategic alliance with Biomimetic Innovations Ltd (“BMI”). In addition, Sanara reaffirmed its plans to introduce the OsStic™ Synthetic Injectable Structural Bio-Adhesive (“OsStic”) to the U.S. commercial market in the first quarter of 2027, following anticipated clearance by the U.S. Food and Drug Administration, to support reduction and provisional fixation treatment of the more than 100,000(2) peri-articular fractures occurring annually nationwide.On January 07, 2026, the Company announced its BIASURGE product received an Innovative Technology contract from Vizient, Inc. (“Vizient”), the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on the recommendation of BIASURGE by hospital experts who serve on one of Vizient’s client-led councils, and it signifies to Vizient clients BIASURGE’s unique qualities that potentially bring improvement to the healthcare industry. The Innovative Technology contract offers Vizient’s extensive network of healthcare facility customers access to BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026. Full Year 2026 Financial Guidance:

The Company expects full year 2026 net revenue to range from $116 million to $121 million, representing growth of approximately 13% to 17%, compared to the midpoint of the expected net revenue range for the full year 2025. “Our team delivered strong performance in 2025, culminating in preliminary net revenue of approximately $103 million, an increase of approximately 19% year-over-year,” stated Seth Yon, Sanara’s President and Chief Executive Officer. “In the fourth quarter of 2025, our preliminary net revenue increased in the range of 11% to 13% year-over-year, excluding approximately $1.8 million of BIASURGE sales in the prior year period, consistent with the range of expectations shared on our Q3 earnings call.(1) Operationally, we made important progress across multiple areas during the fourth quarter. Importantly, we secured a new contract with Vizient, Inc. – the largest group purchasing organization in the U.S. – which significantly expands access to BIASURGE at contracted pricing and pre-negotiated terms. In addition, we enhanced our sales and distribution network, while also working to expand our product portfolio through our initiatives with BMI related to OsStic.”

Mr. Yon continued: “Looking ahead to 2026, we expect to deliver net revenue growth of approximately 13% to 17% year-over-year, fueled primarily by sales of our soft tissue products. We are entering 2026 as a pure play surgical business for the treatment of surgical wounds, which we believe positions Sanara to deliver sustainable, long-term growth and profitability as we expand our share of the multi-billion-dollar surgical solutions market.”

The Company’s independent registered public accounting firm has not completed its procedures with respect to the preliminary financial information or its audit of our financial statements for the year ended December 31, 2025. Actual results may differ from these estimates as a result of the completion of our audit and other developments that may arise between now and the time our financial results for the fourth quarter and fiscal year are finalized.

(1) Net revenue excluding BIASURGE sales in the fourth quarter of 2024 is a non-GAAP financial measure. See the discussion and the reconciliations at the end of this release for additional information.
(2) National Library of Medicine; BMI and Sanara company estimates.

About Sanara MedTech Inc.

Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets, and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company’s products, services, and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara’s products are primarily sold in the North American surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft, FORTIFY FLOWABLE® Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN® Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, and TEXAGEN® Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit SanaraMedTech.com.

Information about Forward-Looking Statements

The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,” “could,” “estimates,” “expect,” “forecast,” “guidance,” “intends,” “may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,” “projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s expected net revenue for the fourth quarter and full fiscal year ended December 31, 2025, the Company’s expected cash balance as of December 31, 2025, the Company’s expected net revenue for the fiscal year ending December 31, 2026, the potential sale of BIASURGE to Vizient clients upon award of the Innovative Technology contract, the Company’s business strategy and mission, the development of new products, the timing of commercialization of the Company’s products, and the regulatory approval process. These items involve risks, contingencies and uncertainties such as the preliminary financial information remaining subject to changes and finalization based upon management’s ongoing review of results for the fourth quarter and full fiscal year 2025 and the completion of all quarter and year-end closing procedures, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by, these statements.

All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.

Investor Relations Contact:

Jack Powell or Mike Piccinino, CFA
ICR Healthcare
[email protected]

SANARA MEDTECH INC. AND SUBSIDIARIES
NON-GAAP FINANCIAL MEASURES (UNAUDITED)

To supplement the Company’s financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we present adjusted net revenue, a non-GAAP financial measure, in this press release, which adjusts net revenue for unusual events, including the $1.8 million of sales of BIASURGE in the fourth quarter of 2024, as a result of supply chain issues and shortages of intravenous fluids and saline solutions experienced by the broader industry due to Hurricane Helene. The Company’s non-GAAP financial measures are not in accordance with, nor an alternative for, measures conforming to GAAP and may be different from non-GAAP financial measures used by other companies.

Reconciliation of Net Revenue to Adjusted Net Revenue:

($ in millions)                      Three Months Ended     Twelve Months Ended      December 31, % Increase  December 31, % Increase   2025  2024  Low High  2025  2024  Low High  Low High       Low High      Net Revenue $27.2 $27.7 $26.3  3% 5% $102.7 $103.2 $86.7  19% 19%BIASURGE sales (1)    -  (1.8)        -  (1.8)    Adjusted Net Revenue (excluding BIASURGE sales) $27.2 $27.7 $24.5  11% 13% $102.7 $103.2 $84.8  21% 22%
(1) Estimated BIASURGE sales related to supply chain issues and shortages of intravenous fluids and saline solutions experienced by the broader industry during the fourth quarter of 2024 due to Hurricane Helene.

WINTER PARK, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a leader in institutional-grade tokenization of commodity assets, today announced that it has delivered an optional prepayment notice to the holder of its Secured Convertible Debentures, YA II PN, LTD., a Cayman Islands exempt limited company (“Yorkville” or “Holder”). It has also issued notice to cancel the Standby Equity Purchase Agreement (the “SEPA”) previously entered into with Yorkville.

Prepayment Notice for Secured Convertible Debentures

As previously disclosed, the Company has outstanding Secured Convertible Debentures dated November 4, 2025, and December 17, 2025, with the Holder in the aggregate principal amount of $50 million (collectively, the “Debentures”). Today, the Company issued an Optional Prepayment Notice (the “Notice”) to Holder, indicating its intention to prepay the entire outstanding Principal balance of $50 million, plus a Prepayment Premium of 10% as provided in the Debentures. Following receipt of the Notice, the Holder has ten (10) trading days to elect to convert all or any portion of the Debentures, and the Company is required to make the prepayment on the eleventh (11th) trading day after the Notice date, after giving effect to any conversions during such period.

Cancellation of Standby Equity Purchase Agreement

As previously disclosed, the Company is party to a SEPA facility with Yorkville, pursuant to which the Company had the right, but not the obligation, to issue and sell to Yorkville up to $1,000,000,000 of its Common Stock, from time to time during the 36-month commitment period under the SEPA, subject to certain terms, limitations and conditions. As provided in the SEPA, the Company has control over the timing and amount of any sales of Common Stock to the Yorkville at its discretion, and as further provided under the SEPA. The Company has not and will not utilize the SEPA.

Today as well, the Company issued a notice of termination of the SEPA.

Additional information regarding the Debentures and the SEPA is included in the Company’s Current Reports on Form 8-K filed with the SEC on July 9, 2025, August 13, 2025, October 29, 2025, November 6, 2025 and December 19, 2025.

Quote from CEO Henry McPhie

“By issuing notice to retire the convertible debenture and notice to cancel the SEPA we are excited to have a clean balance sheet going into a transformative year for Streamex,” said Henry McPhie Co-Founder and CEO of Streamex. “With the highly anticipated GLDY launch coming up and the recently completed equity raise we are in a very strong position for sustained growth.”

About Streamex Corp.

Streamex Corp. (NASDAQ: STEX) is a vertically integrated technology and infrastructure company focused on the tokenization and digitalization of real-world assets. Streamex provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. The company is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.

For more information, visit www.streamex.com or follow the company on X (Twitter).

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will meet the closing conditions in order to obtain the second tranche USD $25 million in financing, whether we will realize the benefits of the agreement(s) described in this press release in a timely manner or at all, whether such definitive agreements will receive required regulatory approvals, and whether we will realize the anticipated benefits of the current transaction in a timely manner or at all. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled “Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.

No Offer or Solicitation

This press release is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Contacts

Streamex Press & Investor Relations:
Adele Carey
Alliance Advisors Investor Relations
[email protected]

Henry McPhie
Chief Executive Officer, Streamex Corp.
[email protected]
www.streamex.com
https://x.com/streamex

January 23, 2026 07:30 ET  | Source: Society Pass Incorporated

NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Society Pass Incorporated (Nasdaq: SOPA) (the “Company” or “SOPA”), Southeast Asia’s (“SEA”) next generation digital ecosystem announces that Litchfield Hills Research LLC (“Litchfield Hills Research”) has issued equity research report update.

Click Here (on SOPA website) or Here (on Litchfield Hills Research website) to view the full Litchfield Hills Research Equity Research Report.

Summary Points:
• Valuation disconnect: Litchfield Hills Research highlights a pronounced sum-of-the-parts valuation disconnect. SOPA’s $18.0M market capitalization implies a substantial holding-company discount to its operating assets and cash, which carry a value of roughly 1,300% of the parent, while assigning no value to non-consolidated AI infrastructure optionality.

• Strategic transformation: SOPA is transitioning from consumer e-commerce into a platform holding company with scalable, cash-generative operating businesses and embedded AI infrastructure optionality. By late 2025, management formally shifted strategy toward higher-margin, infrastructure-oriented assets, citing increasing competition and margin pressure in consumer e-commerce, accelerating global demand for AI inference capacity, and the opportunity to redeploy capital into scalable platforms with operating leverage. This strategic pivot marks a clear departure from SOPA’s earlier consumer-centric model and establishes the foundation for a diversified platform holding company with multiple, complementary operating assets.

• Strong revenue growth: Anchoring near-term value in two consolidated operating platforms. Thoughtful Media Incorporated, a subsidiary of the Company, (“Thoughtful Media” or “TMG”) and NusaTrip International Pte Ltd. (“NusaTrip”), another subsidiary of the Company, drive reported revenue, with consolidated sales forecast to grow from $7.0M in 2025 to $10M by 2027.

• Thoughtful Media: Litchfield Hills Research says Thoughtful Media is shifting toward premium advertising, and launching social commerce, supporting mid-teens growth and sustained profitability. Litchfield Hills Research forecasts 17% revenue CAGR through 2027 for Thoughtful Media. Strategically, Litchfield Hills Research views Thoughtful Media as the keystone asset in SOPA’s emerging model. When combined with SOPA’s developing AI infrastructure initiatives, this structure increasingly resembles an integrated platform holding company rather than a consumer e-commerce operator.

• Thoughtful Media IPO: To unlock the value of this asset, in August 2024 TMG filed for a registration statement for its IPO with a proposed price range of $4.00–$5.00 per share for 3.75 million shares. Based on the 21.55 million shares outstanding reported in the filing, this implies a pro forma equity valuation of approximately $86 million to $107 million. Following the offering, Litchfield Hills Research believes SOPA is expected to retain an approximate 83% majority stake (roughly 17.8 million shares). Assuming that the IPO of Thoughtful Media priced at $4.50 per share, the midpoint of the IPO price range, this stake represents an implied value of $80.1 million for SOPA. This valuation is equivalent to approximately 444% of SOPA’s current total market capitalization of $18.03 million. Notably, TMG was acquired by SOPA in July 2022 for a total consideration of approximately $2.0 million, suggesting a massive potential valuation step-up of nearly 40x upon a successful public listing.

• NusaTrip (Nasdaq: NUTR): NusaTrip is a majority-owned subsidiary of SOPA operating a high-volume, low-take-rate B2B travel infrastructure platform across Southeast Asia. SOPA acquired it for $5.0 million in 2022. Management is currently executing a pivot into the higher-margin hotel sector, leveraging a network of over 1 million properties—including 500,000 self-contracted hotels in SEA—via a strategic partnership with Bookcabin announced in January 2026. In the most recent reported quarter, NusaTrip remained SOPA’s primary revenue engine, accounting for approximately 55% of consolidated revenue ($0.77 million of $1.38 million). NusaTrip operates as an embedded travel infrastructure, processing approximately $250M GMV in 2025 with a path to full-year profitability. The revenue mix of approximately 95% B2B and 5% B2C, with B2C primarily serving as a testing and data-collection channel. It processes a daily volume of roughly 20,000 airline tickets.

• Sapience AI: Seeding AI data-center investments as long-dated upside. Minority, non-consolidated AI infrastructure investments in Central & Eastern Europe offer high-margin optionality, albeit with limited near-term financial visibility.

About Society Pass Inc.
Founded in 2018 as an e-commerce ecosystem in the fast-growing markets of Vietnam, Indonesia, Philippines, Singapore and Thailand, and with offices located in Bangkok, Beijing, Ho Chi Minh City, Hong Kong, Jakarta, Manila, and Singapore, Society Pass Incorporated (Nasdaq: SOPA) is an acquisition-focused holding company operating 4 interconnected verticals (digital media, travel, lifestyle, and alternative intelligence infrastructure).

Society Pass completed an initial public offering and began trading on the Nasdaq under the ticker SOPA in November 2021.

For more information on Society Pass, please visit:

Website at https://www.thesocietypass.com or
LinkedIn at https://www.linkedin.com/company/societypass or
Facebook at https://www.facebook.com/thesocietypass or
X at https://twitter.com/society_pass or
Instagram at https://www.instagram.com/societypass/.

Cautionary Note Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbour” provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s intended M&A strategies, including possible future IPOs as well as the future performance or valuation of its stock. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “will”, “should”, “can have”, “likely” and other words and terms of similar meaning. Forward-looking statements represent Society Pass Incorporated’s current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, including the trading price and volatility of Society Pass Incorporated’s common stock and risks relating to Society Pass Incorporated’s business, identifying potential acquisition targets, proposed IPO of Thoughtful Media, and the return of its investment in Sapience AI Inc.

Media Contact:
Raynuald LIANG
Chief Executive Officer
[email protected]